von Willebrand factor A1 domain – platelet glycoprotein Ib alpha complex (vWF-A1:GPIbα) (vWF-A1:GPIbα)

The von Willebrand factor A1 domain – platelet glycoprotein Ib alpha complex is a critical molecular interaction that mediates the initial step of platelet adhesion to the vascular subendothelium, particularly under high-shear stress conditions [PMID: 11830473]. This complex is formed when the A1 domain of the multimeric glycoprotein von Willebrand factor (vWF) binds to the N-terminal leucine-rich repeat domain of the glycoprotein Ib alpha (GPIbα) subunit, which is part of the platelet GPIb-IX-V receptor complex [UniProt: P04275, P07359]. This interaction is unique because it is shear-dependent; high flow rates induce a conformational change in vWF that exposes the A1 domain for binding [PMID: 15153610]. Pathologically, this interaction is central to the development of microvascular thrombosis in conditions like thrombotic thrombocytopenic purpura (TTP) and contributes to arterial occlusion in myocardial infarction and stroke [PMID: 30625059]. Conversely, genetic defects in vWF or GPIbα result in bleeding disorders such as von Willebrand disease and Bernard-Soulier syndrome, respectively [PMID: 17945331]. Therapeutic targeting of this complex, most notably with the nanobody caplacizumab, has proven effective in preventing the formation of microthrombi by blocking the A1-GPIbα interface [PMID: 30625059]. This complex represents a high-value target for the development of next-generation antithrombotic agents that aim to decouple pathological thrombosis from normal hemostasis.

Other names

vWF-A1:GPIb-IX-V complexvWF-GPIbα interactionPlatelet glycoprotein Ib-von Willebrand factor complexGPIbα-VWF A1 complex

Inhibition of the interaction between the von Willebrand factor A1 domain and the platelet glycoprotein Ib alpha receptor to prevent platelet tethering and aggregation under high shear stress.